skip to Main Content
Wall Street

Valens goes public on the New York Stock Exchange.

Valens Semiconductor, Ltd. (“Valens”), a premier provider of high-speed connectivity solutions for the audio-video and automotive markets, and PTK Acquisition Corp. (NYSE: PTK) (“PTK”), a special purpose acquisition company, today announced the completion of their previously announced business combination (the “Business Combination”). 
Spire News Globe

Spire to expand footprint by acquiring exactEarth

Spire Global, Inc. (NYSE: SPIR), a leading provider of space-based data, analytics and space services, and exactEarth Ltd. (TSX: XCT) (“exactEarth”) announced today that the companies have entered into a definitive arrangement agreement under which Spire will acquire exactEarth for approximately US$161.2 million (CAD$204.2 million) in cash and stock, which implies ~9.1x exactEarth’s Enterprise Value to LTM revenue. 
Spire Global News

Spire goes public through SPAC.

Spire Global, Inc. (“Spire” or the “Company”) a leading global provider of space-based data, analytics and space services, today announced it has completed its previously announced business combination with NavSight Holdings, Inc. (NYSE: NSH) (“NavSight”) to take Spire public.
Valens News

Valens completes Form F-4 registration in preparation of SPAC merger with PTK Acquisition Corp.

Valens Semiconductor, Ltd. (“Valens”), a premier provider of high-speed connectivity solutions for the audio-video and automotive markets, announced today that the registration statement on Form F-4 (as amended, the “Registration Statement”) related to the previously announced business combination (the “Business Combination”) with PTK Acquisition Corp. (NYSE: PTK) (“PTK”), a special purpose acquisition company, has been declared effective by the Securities and Exchange Commission (“SEC”).
RallyBio News

RallyBio goes public.

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the closing of its initial public offering of 7,130,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 930,000 additional shares of common stock, at a public offering price of $13.00 per share.
Back To Top